10054 results about "Virology" patented technology

Among other things, the present disclosure provides various technologies including chirally controlled oligonucleotide compositions and technologies tor manufacturing and using such oligonucleotide compositions. In some embodiments, the present disclosure provides technologies useful for allele -specific knockdown of mutant Huntingtin transcripts. In some embodiments, tire present disclosure provides technologies useful for reducing the expression, level, amount, and / or activity of mutant Huntingtin transcripts or products thereof. In some embodiments, the present disclosure provides methods for treating Huntington's disease.

The invention discloses a primer probe combination and a kit for detecting genital tract pathogenic microorganisms and application. The primer probe combination comprises primer probe sequences as shown in SEQ ID NO.1-SEQ ID NO.96, the genital tract pathogens comprise 27 pathogens capable of causing genital tract diseases, such as ureaplasma parvum, ureaplasma urealyticum, mycoplasma hominis, mycoplasma genitalium, candida albicans, candida glabrata, candida tropicalis, candida auricula, candida krusei and candida duberlin, as well as lactobacillus crispatus, lactobacillus jensenii and lactobacillus gasseri; the lactobacillus lactis comprises four common vaginal lactobacillus lactis, and also comprises a human-derived interior label. On the basis of a fluorescent quantitative PCR technology, the kit can be used for simultaneously detecting 27 pathogens capable of causing genital tract diseases and 4 common lactobacillus vaginalis in an in-vitro sample, not only can cover main pathogens of genital tract infection, but also meets the evaluation on the ecological environment of the vagina, the detection time is shortened to about 40 minutes, and meanwhile, the kit has relatively good specificity and sensitivity.

The invention relates to a mouse anti-PBP2a hybridoma cell strain, a monoclonal antibody and application of the mouse anti-PBP2a hybridoma cell strain, staphylococcus aureus PBP2a protein is extracted as an antigen, after the high-purity antigen is obtained, a good immunoreaction is aroused in a mouse body, then a hybridoma technology is adopted, two cell strains with high affinity and specificity are screened, and the corresponding antibody is prepared; the two antibodies are used as a gold-labeled antibody and a coating antibody in a colloidal gold immunoassay kit, and the kit can be used for detecting PBP2a protein in methicillin-resistant staphylococcus aureus and can be used for developing related in-vitro diagnostic reagents.

Provided are novel antibodies targeting CD3 and one or more other targets, or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical composition comprising the same and the uses thereof.

An anti-human adenovirus (AdV) antibody, a preparation method, a kit comprising the antibody, and the related use thereof. The anti-human adenovirus antibody can specifically bind hexon proteins of various types of adenoviruses, shows high sensitivity and high specificity for adenoviruses, can be used for detecting various types of adenoviruses, greatly increases the detection rate of adenoviruses, reduces the detection cost, and provides a feasible scheme for rapid detection of adenoviruses in the respiratory tract and the digestive tract.

A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.

The present invention provides a method for packaging a BaEV retroviral vector. The method includes constructing a stable BaEV retroviral packaging cell line, transfecting a retroviral vector plasmid containing a target sequence into a virus-producing cell line, where the virus-producing cell line is a HEK293T cell line or its derivative cell line, to harvest the transiently transfected and virus-producing retroviral vector, mixing it with the stable BaEV retroviral packaging cell line, and promoting the transduction of the retroviral vector into the stable BaEV retroviral packaging cell line by horizontal centrifugation. The present invention can achieve the packaging of a BAEV-type retroviral vector carrying a CD19CAR foreign gene plasmid, construct a BAEV-type retroviral vector-producing cell line, and produce a high-titer BAEV-type retroviral vector.

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.

The invention discloses an attenuated salmonella typhimurium EN-VNP (Enhanced Natriuretic Peptide) strain as well as a preparation method and application of the attenuated salmonella typhimurium EN-VNP strain. Comprising the following steps: on the basis of a salmonella VNP20009 strain, flagellin genes fliC and fljB, a phosphoethanolamine transferase gene eptA, a 4-amino-4-deoxy-L-arabinose transferase gene arnT and phosphotransferase yeiU are sequentially knocked out or silenced, and a strain is formed after a phosphotransferase gene lpxE is knocked in or overexpressed, so that the attenuated salmonella typhimurium EN-VNP strain is prepared. According to the attenuated salmonella typhimurium EN-VNP with low toxicity and the T cell adjuvant effect and an EN-OMV antigen delivery system prepared from the attenuated salmonella typhimurium EN-VNP, an improved strain does not contain flagellin, an LPS molecular structure is changed, the attenuated salmonella typhimurium EN-VNP has the low toxicity and the T cell adjuvant effect, and normal multiplication culture can be achieved.

The invention discloses a primer combination for detecting monkey pox viruses and identifying monkey pox viruses Ia, Ib and II, and belongs to the technical field of molecular biology, the nucleotide sequences of specific primers and probes are shown as SEQ ID NO.1-SEQ ID NO.12, and the primer combination aims at solving the problem that in the prior art, new evolutionary branch Ib types of monkey pox viruses cannot be accurately typed, and the detection sensitivity is high. According to the present invention, the defects that the monkey pox virus and the orthopox virus have the cross reaction are overcome, the genome difference of different evolutionary branches is analyzed through the bioinformatics system, the primer probe composition capable of simultaneously detecting the monkey pox virus and carrying out accurate typing is analyzed and screened, and the primer combination can detect 200 copies / mL of the monkey pox virus with high specificity and high sensitivity. Meanwhile, detection of the monkey pox virus and identification of the types Ia, Ib and II of the monkey pox virus are realized in a reaction system, so that different monkey pox branches can be distinguished, and treatment and prevention can be performed in a more targeted manner.

The invention relates to lactobacillus crispatus LC30 for preventing and treating female genital tract infection and application of the lactobacillus crispatus LC30. The lactobacillus crispatus LC30 is preserved in the China General Microbiological Culture Collection Center with the preservation number of CGMCC NO.31923. The lactobacillus crispatus LC30 has good hydrogen peroxide production capacity and adhesion capacity, has a strong inhibition effect on main vaginitis pathogenic bacteria, and can be used for preventing and treating female genital tract infection. The composition is effective to nutritional pathogenic bacteria, and can also reduce form transformation and biological membrane formation of the pathogenic bacteria and prevent and treat drug resistance; besides, the fermentation product can reduce the content of pathogenic bacteria metabolites, regulate the secretion of cytokines and achieve the effect of relieving inflammation, so that the fermentation product can be used for preparing products for preventing and treating genital tract pathogenic bacteria infection, preventing and treating vaginitis and / or removing pudendum peculiar smell.

The invention relates to lactobacillus gasseri FMTA1125B with the effect of preventing, relieving or treating vaginitis and application of the lactobacillus gasseri FMTA1125B. The lactobacillus gasseri FMTA1125B is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1125B is CGMCC No.34292. The lactobacillus gasseri FMTA1125B has the effects of preventing, relieving or treating vaginitis and the application of the lactobacillus gasseri FMTA1125B. The bacterium can produce beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide through metabolism so as to regulate the genital tract environment and improve the health degree; and the traditional Chinese medicine composition has relatively good bacteriostasis and sterilization effects on common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1125B strain can be used for preparing a preparation with the effect of improving related genital tract diseases such as vaginitis.

The present invention provides antibodies, or antigen binding fragments thereof, capable of binding to leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). The invention also provides application of the antibody or the antigen binding fragment thereof in preparation of drugs for treating diseases related to high expression of LILRB2. The antibody or the antigen binding fragment thereof provided by the invention can bind to human LILRB2 with high affinity, block the binding of the LILRB2 and the ligand HLA-G thereof, and enhance the T cell function.

Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and / or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

The invention relates to the technical field of microorganisms, and provides lactobacillus mucilaginosus for maintaining genital tract health and preventing genital tract infection and application of lactobacillus mucilaginosus. Fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection is named as FMTA1113H and is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.34291. The invention further discloses a preparation method of the fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection. According to the technical scheme, the problems that female genital tracts are prone to infection and relapse is prone to occurring after infection in the prior art are solved.

The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

The invention discloses monoclonal antibodies NP5 and NP8 for resisting influenza A virus NP protein and application of the monoclonal antibodies NP5 and NP8, and belongs to the technical field of monoclonal antibodies. According to the invention, 19 influenza A virus NP protein monoclonal antibodies are prepared, and the monoclonal antibodies NP5 and NP8 are obtained by screening through ELISA (enzyme-linked immuno sorbent assay) detection and sequencing analysis. The NP5 comprises a light chain CDR2 of which the amino acid sequence is RTS, light chains CDR1 and CDR3 of which the amino acid sequences are shown as SEQ ID NO.3-4, and heavy chains CDR1-3 of which the amino acid sequences are shown as SEQ ID NO.7-9; the NP8 comprises a light chain CDR2 of which the amino acid sequence is LVS, light chains CDR1 and CDR3 of which the amino acid sequences are as shown in SEQ ID NO.12 to SEQ ID NO.13, and heavy chains CDR1-3 of which the amino acid sequences are as shown in SEQ ID NO.16 to SEQ ID NO.18. The invention lays a foundation for preparing an influenza A virus detection kit.

The invention relates to the field of biological detection, in particular to a primer probe combination and a kit for HIV-1 (human immunodeficiency virus-1) nucleic acid detection. The primer combination provided by the invention comprises a primer group I and / or a primer group II, the primer group I has a nucleotide sequence as shown in any of SEQ ID NO: 1 to SEQ ID NO: 4; the primer group II has a nucleotide sequence as shown in any of SEQ ID NO: 5 to SEQ ID NO: 8. The kit provided by the invention can be stored for 1 year at 2-8 DEG C, and has good stability. Meanwhile, the detection method and the kit provided by the invention have the advantages of strong specificity, high sensitivity, simplicity and convenience in operation, clear result, high reliability and wide coverage. The invention has potential application prospects in detection and identification of HIV-1 and auxiliary diagnosis of HIV infected persons, and has great influence on prevention and treatment of AIDS and public health.

The invention includes a mutant Taq polymerase, which can significantly extend and amplify a target sequence where the extension conditions are time limited to as little as one second. The mutant Taq polymerase, or a biologically active fragment thereof, has one or more substitutions differing from the wild type as shown in Table I.

Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the present disclosure.

The invention belongs to the technical field of biology, and particularly discloses application of moxidectin in preparation of a medicine for preventing and treating rotavirus. Compared with the prior art, the invention discovers that the moxidectin can significantly inhibit RV replication, and discovers that the moxidectin not only inhibits transcriptional level expression of VP6 protein of rotavirus, but also can reduce the expression level of the VP6 protein. Therefore, moxidectin can be used for preventing or treating rotavirus.

The invention provides preparation of an anti-p-Tau217 antibody and application of the anti-p-Tau217 antibody in an Alzheimer's disease detection kit, and belongs to the technical field of antibodies and immunodetection, the anti-p-Tau217 antibody comprises a heavy chain variable region and a light chain variable region, a coding gene of the heavy chain variable region comprises a nucleotide sequence shown in SEQ ID NO.1, and a coding gene of the light chain variable region comprises a nucleotide sequence shown in SEQ ID NO.2. The coding gene of the light chain variable region comprises a nucleotide sequence shown in SEQIDNO.3, the heavy chain variable region comprises an amino acid sequence shown in SEQIDNO.2, and the light chain variable region comprises an amino acid sequence shown in SEQIDNO.3. The invention also discloses a preparation method. The invention provides preparation of an anti-p-Tau217 antibody and application of the anti-p-Tau217 antibody in an Alzheimer's disease detection kit. The successful expression of the monoclonal anti-p-Tau217 antibody with high affinity is realized, and the monoclonal anti-p-Tau217 antibody is used for detecting the Alzheimer's disease.

The invention belongs to the technical field of monoclonal antibody preparation, and particularly relates to a human-mouse chimeric monoclonal antibody for resisting human G protein-coupled receptor family member 1 (LGI1 protein) as well as a product and application of the human-mouse chimeric monoclonal antibody. The variable regions of the heavy chain and the light chain of the human-mouse chimeric monoclonal antibody of the anti-human LGI1 protein come from mice, and the constant regions of the heavy chain and the light chain of the human-mouse chimeric monoclonal antibody are human antibody constant regions, so that the human-mouse chimeric monoclonal antibody can replace the function of serum to a certain extent on the basis of retaining parent activity to the greatest extent; meanwhile, the technical problems that the Fc region of the existing anti-human LGI1 protein monoclonal antibody cannot react with the anti-human IgG antibody, the sensitivity difference among multiple batches of antibodies is large, and batch production cannot be realized can be solved. Furthermore, the human-mouse chimeric monoclonal antibody of the anti-human LGI1 protein can be used for detecting the LGI1 protein and an LGI1 autoantibody.

The invention discloses an intestinal flora marker related to Parkinson's syndrome and application of the intestinal flora marker. The invention discloses an intestinal flora marker, which comprises one or a combination of more of bacteroides faecalis, bacteroides vulgaris, bacteroides thetaotamicrobe, ruminococcus ruminococcus and lactobacillus salivarius, and is characterized in that the intestinal flora marker comprises one or a combination of more of bacteroides faecalis, bacteroides vulgaris, bacteroides thetaotamicrobe, ruminococcus ruminococcus and lactobacillus salivarius, and the intestinal flora marker comprises one or a combination of more of the bacteroides vulgaris, the bacteroides vulgaris, the bacteroides thetaotamicrobe, the ruminococcus ruminococcus and the lactobacillus salivarius. The intestinal flora marker is used as a detection marker to be applied to diagnosis of Parkinson's syndrome patients, and is completely noninvasive and high in accuracy.

The invention discloses preparation of an antibody capable of detecting multi-subtype KPC and application of a kit of the antibody, and belongs to the field of biological medicine. According to the kit for detecting the common subtypes of KPC and the application of the kit, the mouse antibodies are prepared through immunization of conserved antigen epitopes of all the subtypes of KPC, in-vitro screening and pairing are carried out in multiple modes, then an antibody pair which is good in specificity and high in affinity and can be combined with multiple subtypes is obtained, the titer of the two antibodies can reach one million or above, and the kit is high in specificity, good in affinity and capable of being used for detecting the common subtypes of KPC. Amino acid sequences of a heavy chain variable region and a light chain variable region are obtained through sequencing, and rapid and stable expression can be realized after recombination. The product for detecting the carbapenem KPC is developed on the basis of an immunochromatography platform, and the kit has the advantages of high sensitivity, good specificity, good stability, capability of covering most epidemic KPC subtypes and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.

The invention discloses a novel acinetobacter baumannii phage vBAbaSqsb1 and application thereof, and belongs to the technical field of microorganisms. The bacteriophage is an Acinetobacter baumannii bacteriophage vBAbaSqsb1 which is preserved in the Guangdong Microbiological Culture Collection Center on July 5, 2024, the preservation number is GDMCC (China General Microbiological Culture Collection Center) NO: 64831-B1, and the preservation address is Institute of Microbiology of Academy of Sciences of Guangdong Province. The bacteriophage can specifically recognize and split the acinetobacter baumannii so as to eliminate infection and overcome the problem of antibiotic resistance of the acinetobacter baumannii. Through discovery and application research of the phage vBAbaSqsb1, the phage vBAbaSqsb1 not only can be used for preparing a phage preparation for preventing and treating diseases caused by acinetobacter baumannii infection, but also can be used for preparing various environmental bactericides for solving potential acinetobacter baumannii in various environments. The bacteriophage vBAbaSqsb1 has the characteristics of safety, no toxic or side effect and the like, so that the problem of drug resistance caused by abuse of antibiotics can be avoided when the bacteriophage vBAbaSqsb1 is applied.

The invention belongs to the field of biomedicine, and particularly relates to application of ABCG1 in diagnosis or auxiliary diagnosis of HIV (human immunodeficiency virus) combined hyperlipidemia. Through detection, the expression of the ABCG1 in the blood of a patient with HIV combined with hyperlipidemia is obviously reduced, the ABCG1 is verified to have the characteristics of high sensitivity and high specificity, whether hyperlipidemia exists in an HIV infected group or not can be diagnosed or diagnosed in an auxiliary manner by detecting the expression of the ABCG1, guidance is provided for early intervention of hyperlipidemia in the HIV infected group, and the method is suitable for clinical application. Wide clinical application prospects are realized.

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.